Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI106029

Intestinal β-galactosidases: I. Separation and characterization of three enzymes in normal human intestine

Gary M. Gray and Nilda A. Santiago

Department of Medicine, Stanford University School of Medicine, Stanford, California 94305

Find articles by Gray, G. in: PubMed | Google Scholar

Department of Medicine, Stanford University School of Medicine, Stanford, California 94305

Find articles by Santiago, N. in: PubMed | Google Scholar

Published April 1, 1969 - More info

Published in Volume 48, Issue 4 on April 1, 1969
J Clin Invest. 1969;48(4):716–728. https://doi.org/10.1172/JCI106029.
© 1969 The American Society for Clinical Investigation
Published April 1, 1969 - Version history
View PDF
Abstract

Previous studies based on work in the rat and preliminary experiments with human intestine have suggested that two β-galactosidases are present in small intestine, and it is believed that only one of these enzymes is a lactase important for the digestion of dietary lactose. The high prevalence of intestinal lactase deficiency in man prompted more complete study of these enzymes.

Human intestinal β-galactosidases were studied by gel filtration on Sephadex G-200 and Biogel P-300 as well as by density gradient ultracentrifugation. Gel filtration produced partial separation into three peaks of enzyme activity, but much activity against synthetic substrates was lost. Only the trailing peak with specificity for synthetic β-galactosides was completely separated from the other enzymes. Thus gel filtration was not a suitable preparative procedure for biochemical characterization.

Density gradients separated the enzymes more completely, and they were designated according to their sedimentation rates and further characterized. Enzyme I has a molecular weight of 280,000, pH optimum of 6.0, and specificity for lactose of at least five times that for cellobiose or synthetic substrates. A second lactase, enzyme II, possesses slightly greater activity against lactose than for some synthetic substrates and is incapable of splitting cellobiose. Further, it has a lower pH optimum (4.5) and is present in two molecular species (molecular weights 156,000 and 660,000). Enzyme III shows specificity only for synthetic β-galactosides but has a pH activity curve identical with enzyme I and a molecular weight of 80,000. Whereas human liver and kidney contain a β-galactosidase with the same biochemical characteristics as intestinal enzyme II, enzymes I and III appear to be peculiar to intestine, and enzyme I most probably represents the lactase of importance in the mucosal digestion of dietary lactose. The following paper considers this further in terms of the biochemical change in intestinal lactase deficiency.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 716
page 716
icon of scanned page 717
page 717
icon of scanned page 718
page 718
icon of scanned page 719
page 719
icon of scanned page 720
page 720
icon of scanned page 721
page 721
icon of scanned page 722
page 722
icon of scanned page 723
page 723
icon of scanned page 724
page 724
icon of scanned page 725
page 725
icon of scanned page 726
page 726
icon of scanned page 727
page 727
icon of scanned page 728
page 728
Version history
  • Version 1 (April 1, 1969): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts